Modulation of Interleukin‐23 Signaling With Guselkumab in Biologic‐Naive Patients Versus Tumor Necrosis Factor Inhibitor–Inadequate Responders With Active Psoriatic Arthritis

Documenti analoghi

• Guselkumab Safety in Patients With Latent Tuberculosis: Analysis of 11 Studies in Psoriatic Disease
  di: Luis Puig, et al.
  Pubblicazione: (2026)
• Improvements in Patient‐Reported Outcomes Through Six Months of Guselkumab Treatment in Patients With Active Psoriatic Arthritis: Real‐World Data From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
  di: Philip J. Mease, et al.
  Pubblicazione: (2024)
• Improvements in Patient‐Reported Outcomes After Treatment With Deucravacitinib in Patients With Psoriatic Arthritis: Results From a Randomized Phase 2 Trial
  di: Vibeke Strand, et al.
  Pubblicazione: (2024)
• 77 | Markers of IL‐17 Signalling in the Blood of Patients With Psoriatic Arthritis (PsA) With Inadequate Response to Tumour Necrosis Factor Inhibitors (TNFi‐IR)
  Pubblicazione: (2026)
• CAR T‐cell therapy in autoimmune skin disease
  di: Antonia Schett, et al.
  Pubblicazione: (2026)